
    
      The primary objectives of the study are the continuation of rogaratinib treatment (as
      monotherapy or combination therapy) for patients after closure of their feeder studies and
      the further assessment of the safety of the drug.

      The secondary objective is to investigate the tolerability of rogaratinib.
    
  